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Abstract
Background: Defining the optimal treatment for patients with inoperable non small cell lung cancer (NSCLC),
presenting with metastatic mediastinal lymph nodes, is challenging. Nevertheless, preoperative chemotherapy or
radiotherapy might offer a chance for these patients for radical surgical resection and, possibly, complete recovery.
Case Presentation: A 62-year old man with IIIA-N2 inoperable NSCLC was treated with first-line single agent
docetaxel. A platinum-based treatment, though considered more active, was ruled out because of renal impairment.
The patient tolerated the treatment very well and, although his initial response was not impressive, after 14 cycles he
obtained a complete clinical response, which was confirmed pathologically after he underwent surgical lobectomy.
Conclusion: In non-operable NSCLC patients not eligible for a platinum-based treatment, single-agent docetaxel
can provide complete pathologic responses. Failure to obtain a response after the first few cycles should not
automatically discourage to continue treatment.
Introduction
In non-small cell lung cancer (NSCLC), mediastinal
lymphnode involvement comprises a wide spectrum of
severity. In fact, while 9% of patients with IIIA-N2
NSCLC is candidate for surgery at diagnosis, with a 5-
year survival of 20-30%, the majority of patients with
stage IIIA-N2 and IIIB-N2 tumors cannot undergo up-
front surgical resection and present a 5-year survival
rate of about 5%[1]. There is a growing body of evidence
that suggests that neoadjuvant chemotherapy or radio-
therapy or chemoradiotherapy prior to surgery can be
advantageously employed in patients with stage IIIA-N2
disease[2]. We herein describe an unusual case of patho-
logical complete response induced by single agent doce-
taxel chemotherapy in a patient with diagnosis of
NSCLC initially judged not fit for surgical resection.
Case Presentation
A 62-year-old man was referred to Cardarelli Hospital,
Naples, in June 2008. He presented a 4-month history of
non productive cough, progressive shortness of breath,
increasing abdominal girth and anorexia. He was mildly
dyspnoeic at rest and complained about severe asthenia.
There was no alcohol abuse in the previous ten years,
while he presented an 80-pack-a year history of cigarette
use, as he had smoked since the age of 18 until recently.
An abnormal shadow appeared on the patient’s chest X-
ray, while a CT scan revealed a right hilar tumor, mea-
suring 92 × 66 mm, as shown in Figure 1.
Af i b e r o p t i cb r o n c h o s c o p yi n d i c a t e dt h ep r e s e n c eo f
an endobronchial lesion infiltrating the upper lobar
bronchus of the right lung. Pathological analysis with
CT-guided fine-needle aspiration biopsy (FNAB) of the
collected specimens showed that the tumor was a
poorly differentiated squamous cell carcinoma. There
was no evidence of extra thoracic metastasis on brain
MRI, abdominal CT and FDG-PET scans. Therefore,
the patient had a stage IIIA-N2 NSCLC.
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mated creatinine clearance of 47 ml/min. Considering
the impaired renal function, a platinum-based treat-
ment was ruled out. Therefore, the patient was started
on single-agent docetaxel induction chemotherapy (75
mg/sqm over 60 min on day 1, every 3 weeks). The
first evaluation was made after four cycles. In Septem-
ber 2008, a CT scan showed a partial response of the
carcinoma, which appeared to measure 65 × 41 mm.
The safety profile was good, with patient reporting
grade 1 anemia, grade 3 neutropenia without fever,
weight loss inferior to 10% and asthenia. Therefore,
the treatment was continued for four additional cycles.
In January 2009, a CT scan showed an impressive
shrinkage of the hilar mass, measuring 35 × 30 mm.
There also was a marked clinical improvement, as the
cough and the dyspnoea had disappeared and the
patient reported a general feeling of wellness. Consid-
ering the patient’s good compliance, it was decided to
continue the same treatment until progression or
unacceptable toxicity. After 14 cycles, both CT and
PET scans showed further tumor response, as the right
hilar mass measured only 16 × 10 mm, and the patient
was finally judged to be eligible for surgery (figures 2
and 3). The chest surgeon decided to perform a right
lobectomy with mediastinal lymph node sampling. On
pathological examination, the response to induction
chemotherapy was complete.
Discussion
Preoperative, platinum-based combination chemother-
apy is safe and active in NSCLC, although a randomized
trial reported a modest, not statistically significant
excess of post-surgical morbidity and mortality[3]. As
single-agent therapy is associated to a lower response
rate, but also to lower toxicity[4], single-agent docetaxel
chemotherapy might be feasible for preoperative ther-
apy, especially in the context of an early stage disease to
be cured with surgery and adjuvant therapy, as well. A
phase III trial randomized patients with stage IIIA or
locally treatable IIIB NSCLC to neoadjuvant docetaxel
(up to three 3-weekly cycles at 100 mg/m
2, 134 patients)
or no chemotherapy (140 patients) prior to surgery/
curative-intention radiotherapy. Treatment proved to be
safe and well tolerated, but this trial showed only a
trend in survival prolongation (14.8 months in the che-
motherapy group vs. 12.6 months in the control group,
not statistically significant)[5]. A multicenter phase III
trial indicated that patients with advanced NSCLC
receiving the combination of docetaxel and cisplatin
(DC) had a statistically significant improvement in
objective response rate compared with patients treated
with docetaxel alone (D), although there was no statisti-
cally significant difference in overall survival (36% vs.
18% and 10.5 vs. 8.0 months, respectively). Furthermore,
patients treated with single-agent docetaxel had a more
favorable toxicity profile than patients treated with DC.
In particular, there were important differences in the
incidence of: (a) grade 2 anemia, (b) grade 3/4 nausea/
vomiting, diarrhea, and neurotoxicity, (c) nephrotoxicity
of any grade and (d) treatment-related deaths (5 in the
DC arm vs 1 in the D arm)[6].
Similarly, the toxicity profile of the monotherapy arm
in the Lilenbaum [7] study was more favorable
Figure 1 CT scan on June 2008.
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difference in survival.
Although it is generally believed that best responses
are obtained in patients who initially respond to doce-
taxel treatment, the case presented herein proves how
an unexpected, striking complete pathologic response
can be achieved with a long-term treatment, which was
substantially well tolerated. Such an observation, if con-
firmed by large-sample studies, might indicate how an
unsatisfactory initial response, but not progressive dis-
ease, does not constitute a reliable predictive factor for
response, as a great improvement in response itself can
still be obtained, if treatment is continued. Noteworthy,
such a result appears to be in contrast with observations
regarding neo-adjuvant docetaxel-based chemotherapy
in other inoperable malignant tumors, such as breast
cancer[8].
Surprisingly, a complete pathologic response was not
obtained with a platinum-based regimen, but with sin-
gle-agent docetaxel, which is not considered to be the
first-line chemotherapy for non-operable patients with
NSCLC. The search for either molecular or genetic mar-
kers predictive for docetaxel sensitivity might constitute
future targets of investigation.
Finally, we cannot but underline our decision not to
suspend treatment as soon as the patient was considered
to be eligible for surgery. In fact, our choice to continue
docetaxel chemotherapy resulted in further tumor
shrinkage, with no additional toxicity, and gave the
patient the possibility to undergo a lobectomy rather
than a pneumectomy, with the obvious advantages of a
less invasive and more limited surgical operation. Our
patient obtained a striking response to docetaxel as
first-line monotherapy treatment and could undergo an
upper right lobectomy with radical intent. Microscopic
examination showed a pathological complete response
of the neoplasia.
Conclusion
Our results suggest that physicians should be aware of
potential objective responses to Docetaxel, as first-line,
for patients with limitations to receive platinum-based
regimens, even after the tumor does not seem to be
reduced in size at the beginning phase of the treatment.
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Figure 2 Chest computed tomography scan (A) before
treatment of docetaxel (B) 10 months after treatment. The
arrows show the mediastinal lymph node metastasis that gradually
reduced in size.
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Figure 3 (A) CT scan June 2008 before therapy. (B) CT scan April 2009 after therapy.
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